{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.75","upperLimit":"7.39","value":"4.76"},{"groupId":"OG001","lowerLimit":"2.04","upperLimit":"4.57","value":"3.84"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"139"}],"units":"Participants"}],"description":"The Functional Assessment of Cancer Therapy - Kidney Symptom Index, Disease Related Symptoms (FKSI-DRS) is a set of items to assess symptoms experienced by patients with advanced kidney cancer. These symptoms include fatigue, pain, weight loss, dyspnea, cough, fever and hematuria. There were 4 response categories (1=Not at all, 2= A little, 3=Quite a bit, 4=Very much), sum of item responses can range from 0 to 36. \"0\"= severely symptomatic patient and the highest score is an asymptomatic patient. Definitive deterioration of the FKSI-DRS score was defined as a decrease by at least 2 units compared to baseline, with no later increase above this threshold observed during the study. A single measure reporting a decrease of at least 2 units was considered definitive only if it is the last one available for the patient. Time to definitive deterioration is the number of days between the date of randomization and the date of the assessment at which definitive deterioration is seen.","dispersionType":"95% Confidence Interval","groups":[{"description":"The study drugs were self administered by the patients. Patients were instructed to take the study drug as specified in the protocol. Patients were instructed to take two tablets (5 mg each) by mouth every day. Tablets were to be taken one tablet after another with a glass of water, at the same time each day in a fasting state or with a light fat-free meal. If disease progression occurred at data cutoff of 28Feb2008, patients were unblinded and if they were receiving RAD001, they would discontinue the study. Otherwise, they would be given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.","id":"OG000","title":"RAD001 +BSC"},{"description":"Patients received matching placebo of RAD001 tablets twice a day along with Best Supportive Care. With the documented disease progression at data cutoff of 28Feb2008, the investigator could unblind the patient. If unblinded patient was receiving placebo treatment, they were given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.","id":"OG001","title":"Placebo + BSC"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set was performed on the intent-to-treat population which consisted of all randomized patients.","reportingStatus":"POSTED","timeFrame":"Baseline and every 28 days under treatment and at discontinuation from RAD001\" until 28Feb2008 cutoff date","title":"Time to Definitive Deterioration of the FKS-DRS Risk Score by at Least 2 Score Units Using Kaplan-Meier Method, by Treatment.","type":"SECONDARY","unitOfMeasure":"months"}